Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Clinical trial NCT04522544 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04522544
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-15
- Primary completion
- 2027-07-31
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.